Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel (Japan)
This article was originally published in PharmAsia News
Daiichi Sankyo and Eli Lilly announced plans to initiate a new Phase III clinical trial comparing their new heart treatment, prasugrel, to its major competitor. Starting in the second quarter of 2008, prasugrel will be matched up against clopidogrel, also known as Plavix. The trial will study 10,000 patients with acute coronary syndrome (ACS). The drugs will be tested for both safety and effectiveness in preventing problems associated with ACS including cardiovascular death, heart attack and stroke. (Click here for more
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.